Graft-vs-Host Disease (GVHD) — Deal Benchmarks & Valuation
Market Analysis
Graft-vs-Host Disease (GVHD) is one of the most actively transacted indications in immunology licensing. Phase 1 deals for graft-vs-host disease (gvhd) carry a median total deal value of $3.5B, with upfront payments ranging from $160M to $560M. The recommended deal structure allocates approximately 10% to upfront payments and 90% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for graft-vs-host disease (gvhd) licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating